NanoBio, an Ann Arbor–based developer of anti-infective products and mucosal vaccines, announced the closing of a $22 million Series B financing round with contributions from Venture Investors and majority shareholder Perseus. Nanobio’s...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)